The fraud investigations of Bristol-Myers Squibb and the University of Medicine and Dentistry of New Jersey posed a dilemma for U.S. Attorney Christopher Christie: how to enforce the law without putting them out of business. Christie chose deferred prosecution, which is relatively new terrain in white-collar cases. Perhaps that's one reason why his deferred prosecutions came under fire at an ABA symposium for what was called excessive prosecutorial involvement in business operations.
Deferred White-Collar Prosecutions: New Terrain, Few Signposts
New Jersey Law Journal
April 11, 2006